The case for complement component 5 as a target in neurodegenerative disease.
Amelia Stennett1, Kallie Friston1, Claire L Harris2
1School of Natural and Environmental Sciences, Newcastle University, NE1 7RU, Newcastle-Upon-Tyne, UK.
Expert Opinion on Therapeutic Targets
|February 14, 2023
Summary
Complement component C5 shows therapeutic potential for neurodegenerative diseases. Further research is needed to understand targeting C5 and its fragments (C5a, C5b) for effective treatment without increasing infection risk.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Complement-based drug discovery is advancing, with C1q and C3 studied for neurodegenerative diseases.
- C5 is a promising therapeutic target in neurodegenerative disease, evidenced by C5 inhibitor eculizumab's success.
Purpose of the Study:
- To review evidence for C5 as a neurodegenerative disease target.
- To discuss progress in developing C5 inhibitors.
- To identify knowledge gaps for advancing C5-targeted therapies.
Main Methods:
- Literature review of complement biology and neurodegenerative disease research.
- Analysis of current C5 inhibitor development.
- Identification of challenges in targeting C5.
Main Results:
- C5 presents significant therapeutic potential for neurodegenerative diseases.
- Various classes of C5 inhibitors are in development.
- Understanding C5a/C5b targeting and infection risk are key challenges.
Conclusions:
- Validating C5 as a target could lead to disease-modifying drugs for neurodegenerative conditions.
- Further biological understanding and improved tools are crucial for C5-targeted therapies.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
235
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
235
01:27Complement System
2.5K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
2.5K
01:26Alzheimer's Disease: Overview
591
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
591
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
174
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
174
01:24Parkinson's Disease: Treatment
327
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
327
01:37Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K